Peptides9 min read
Tesamorelin and visceral fat: what the evidence actually covers
Tesamorelin’s visceral-fat results concern a specific tissue and clinical population. Learn what they do—and do not—say about weight and body shape.
Read articleBlog
Research, explained. Explore peptides, supplements, hormone health, longevity and red light therapy with clear, practical breakdowns of what the studies actually tell us.
Explore the articles
Find a topic you’re curious about and take a closer look.
Peptides9 min read
The 2025 TESTS trial: why immune theories must face patient outcomes
The corrected TESTS trial did not demonstrate a sepsis survival benefit from thymosin alpha-1. Its results show why an immune mechanism needs a clinical test.
Read article
Supplements9 min read
D-mannose for recurrent UTIs: what changed after the larger trial?
A large placebo-controlled trial changed the D-mannose prevention discussion. Understand its findings, limits and implications for an existing routine.
Read article
Supplements8 min read
Biotin and blood tests: when a supplement changes the result
Biotin can alter laboratory measurements without changing the underlying hormone level. Understand the tests, timing and practical preparation.
Read article
TRT9 min read
Why TRT's blood-pressure warning deserves its own headline
Blood pressure and major cardiovascular events answer different safety questions. Learn what testosterone monitoring studies show and how to collect useful readings.
Read article
TRT9 min read
TRT and prostate safety: what TRAVERSE can—and cannot—tell us
TRAVERSE found uncommon prostate events in carefully screened men. Learn what its results mean for PSA changes, urinary symptoms and longer-term uncertainty.
Read article
HRT9 min read
Patches Versus Pills: What Route Can Change About HRT Risk
Why delivery through skin changes the evidence on venous clots, and why dose, progestogen and individual history still matter.
Read article
HRT8 min read
HRT and GLP-1 treatment: separate goals, coordinated care
Separate the benefits, evidence and monitoring needs of HRT and GLP-1 treatment, including oral progestogen and contraception questions.
Read article
Peptides9 min read
Why online retatrutide cannot borrow a trial's quality assurances
What trial-quality retatrutide means, why purity is only one question, and what an online vial's name or certificate cannot establish.
Read article
Peptides9 min read
Does CagriSema evidence support adding cagrilintide to tirzepatide?
CagriSema trials, tirzepatide comparisons and a newly listed add-on study answer different questions. Here is what each can support.
Read article
Peptides11 min read
SS-31 before MOTS-c: what each peptide does and what the research shows
SS-31 and MOTS-c have different roles in mitochondrial research. Human studies explain some of the interest, but do not establish a benefit from using them in sequence.
Read article
Supplements9 min read
Berberine is not a supplement version of a GLP-1 drug
The 2025 HTD1801 trial improved HbA1c but did not reduce weight. Its findings cannot turn ordinary berberine into a GLP-1 substitute.
Read article110–121 of 600 articles